Long-Term Efficacy of Adjunctive Cariprazine in Patients With MDD: Results From an Open-Label 26-Week Safety Study

被引：0
|
作者：
Masand, Prakash [1 ]
Vieta, Eduard [1 ]
Waraich, Simranpreet [1 ]
Kramer, Ken [1 ]
Kerolous, Majid [1 ]
机构：
[1] AbbVie, New York, NY USA
来源：
NEUROPSYCHOPHARMACOLOGY | 2023年 / 48卷
关键词：
Cariprazine; Major Depressive Disorder; Depression; Adjunctive; Long-Term;
D O I：
暂无
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
P343
引用
收藏
页码：263 / 264
页数：2
相关论文
共 50 条
  • [1] Long-term safety of adjunctive brexpiprazole (OPC-34712) in MDD: results from two 52-week open-label studies
    Nelson, Craig
    Skuban, Aleksandar
    Zhang, Peter
    Weiller, Emmanuelle
    Weiss, Catherine
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2016, 19 : 103 - 103
  • [2] Evaluation of the long-term safety and tolerability of cariprazine in patients with schizophrenia: results from a 1-year open-label study
    Cutler, Andrew J.
    Durgam, Suresh
    Wang, Yao
    Migliore, Raffaele
    Lu, Kaifeng
    Laszlovszky, Istvan
    Nemeth, Gyorgy
    CNS SPECTRUMS, 2018, 23 (01) : 39 - 50
  • [3] Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study
    Tepper, Stewart J.
    Ashina, Messoud
    Reuter, Uwe
    Brandes, Jan Lewis
    Dolezil, David
    Silberstein, Stephen D.
    Winner, Paul
    Zhang, Feng
    Cheng, Sunfa
    Mikol, Daniel D.
    CEPHALALGIA, 2020, 40 (06) : 543 - 553
  • [4] Long-term safety and tolerability of open-label cariprazine in patients with bipolar I disorder
    Ketter, T. A.
    Sachs, G.
    Lu, K.
    Laszlovszky, I.
    Nagy, K.
    Starace, A.
    Durgam, S.
    BIPOLAR DISORDERS, 2013, 15 : 134 - 134
  • [5] Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week, single-arm, open-label extension study
    Suresh Durgam
    William M. Greenberg
    Dayong Li
    Kaifeng Lu
    Istvan Laszlovszky
    Gyorgy Nemeth
    Raffaele Migliore
    Stephen Volk
    Psychopharmacology, 2017, 234 : 199 - 209
  • [6] Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week, single-arm, open-label extension study
    Durgam, Suresh
    Greenberg, William M.
    Li, Dayong
    Lu, Kaifeng
    Laszlovszky, Istvan
    Nemeth, Gyorgy
    Migliore, Raffaele
    Volk, Stephen
    PSYCHOPHARMACOLOGY, 2017, 234 (02) : 199 - 209
  • [7] Adjunctive brexpiprazole for elderly patients with major depressive disorder: An open-label, long-term safety and tolerability study
    Lepola, Ulla
    Hefting, Nanco
    Zhang, Doris
    Hobart, Mary
    INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2018, 33 (10) : 1403 - 1410
  • [8] Long-term safety and effectiveness of brexpiprazole in Japanese patients with schizophrenia: A 52-week, open-label study
    Ishigooka, Jun
    Iwashita, Shuichi
    Tadori, Yoshihiro
    PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2018, 72 (06) : 445 - 453
  • [9] Long-term safety of adjunctive cenobamate in patients with uncontrolled focal seizures: Open-label extension of a randomized clinical study
    French, Jacqueline A.
    Chung, Steve S.
    Krauss, Gregory L.
    Lee, Sang Kun
    Maciejowski, Maciej
    Rosenfeld, William E.
    Sperling, Michael R.
    Kamin, Marc
    EPILEPSIA, 2021, 62 (09) : 2142 - 2150
  • [10] Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: Results from a phase III open-label extension trial
    Husain, Aatif
    Chung, Steve
    Faught, Edward
    Isojarvi, Jouko
    McShea, Cindy
    Doty, Pamela
    EPILEPSIA, 2012, 53 (03) : 521 - 528
12345